RxDoctor Payments Data

Golali Nejati, MD

Internal Medicine · Brooklyn, NYNPI 1922231604

Payments from drug & device makers

$517in general payments, 2019–2025

Across 22 payments — averaging $23.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$169
  • Alnylam Pharmaceuticals Inc.$133
  • Bayer$60
  • Amarin Pharma, Inc.$43
  • Boehringer Ingelheim$29
  • Shield Therapeutics Inc$25
  • plus $58 from 3 others

What the payments were for

  • Food & beverage$517100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$517 in reported general payments places this provider in the 60th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$39,106
Medicare patients
16
Services billed
2,052

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin323$312,498
JanuviaSitagliptin Phosphate264$224,869
Metformin Er GastricMetformin Hcl41$154,049
JanumetSitagliptin Phos/Metformin Hcl168$129,991
KerendiaFinerenone104$120,115
Diclofenac Sodium148$73,245
TradjentaLinagliptin66$67,487
MounjaroTirzepatide62$66,454
Doxepin Hcl128$65,366
TrulicityDulaglutide50$59,527
VascepaIcosapent Ethyl133$58,957
EntrestoSacubitril/Valsartan40$49,133
XifaxanRifaximin15$48,568
OzempicSemaglutide34$41,368
XareltoRivaroxaban33$31,821

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$29$379,985389 claims
Lilly USA, LLCMounjaro, Trulicity$169$125,981112 claims
BayerKerendia$60$120,115104 claims
AstraZenecaFarxiga$16$15,70315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →